- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02113800
Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)
The study is designed as an open-label, prospective, single arm, multicenter study of everolimus in histologically confirmed, neuroendocrine carcinoma G3 /neuroendocrine tumor G3 after failure of first-line platin-based chemotherapy (open-label pilot study).
The aim of this study is to provide a second line therapy to patients with any type of platinum based first line chemotherapy, to gather data on disease control rate and progression free survival.
Study Overview
Status
Conditions
- Neuroendocrine Carcinoma, Grade 3
- Poorly Differentiated Malignant Neuroendocrine Carcinoma
- Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3
- Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma] That Switched to G3
- Neuroendocrine Tumor, Grade 3 and Disease Progression as Measured by Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
Intervention / Treatment
Detailed Description
As more efficient drugs are urgently needed for the treatment of neuroendocrine tumors the investigator evaluated phosphorylated Mammalian target of rapamycin (mTOR) and effectors in a series of NEC G3 at the Charité Center. Everolimus showed antiproliferative effects in bronchial NET.
In a second approach the data of this study should be the basis to generate another study to further explore everolimus as maintenance therapy in NEC G3/ NET G3.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Berlin, Germany, 13353
- Charité-Universitätsmedizin, Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Campus Virchow-Klinikum
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed written informed consent
- Male or female ≥ 18 years of age
- Patients with poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC - G3 according to WHO 2010) or well or moderately differentiated neuroendocrine carcinoma (NET - G1 / G2) that switched to G3 (confirmed by histology) or neuroendocrine tumor G3 (NET G3) and disease progression as measured by RECIST 1.1
- Progression during or after treatment with first-line platinbased chemotherapy. In NET G3 that switched from NET G2 the line of therapy is determined from the time of revised histology (confirming a G3 NEN)
- Measurable disease according to RECIST 1.1
- Performance Status according to Eastern Cooperative Oncology Group (ECOG) status 0 - 2 (Karnofsky Performance status ≥ 80%)
- Women of child-bearing potential must have a negative pregnancy test
Laboratory requirements:
Hematology
- Absolute neutrophil count ≥ 1.5 x 109/L
- Platelet count ≥ 100 x 10^9/L
- Leukocyte count ≥ 3.0 x 10^9/L
- Hemoglobin ≥ 9 g/dL or 5.59 mmol/L
Hepatic Function
- Total bilirubin ≤ 1.5 time the upper limit normal (ULN)
- Aspartate Aminotransferase (AST) ≤ 3 x ULN in absence of liver metastases, or ≤ 5 x ULN in presence of liver metastases
- Alanine Aminotransferase (ALT) ≤ 3 x ULN in absence of liver metastases, or ≤ 5 x ULN in presence of liver metastases
Renal Function
- Creatinine clearance ≥ 50 mL/min according to cockroft-Gault formula
Metabolic Function
- Magnesium ≥ lower limit of normal
- Calcium ≥ lower limit of normal
Others:
- CRP (PCT if CRP is elevated to exclude infection)
- negative urinary screening test for leukocytes and nitrite (U - stix) to exclude urinary tract infection
Exclusion Criteria:
- Known or suspected allergy or hypersensitivity reaction to any of the components of study treatment or their excipients.
- Previous therapy with mTOR inhibitor
Radiotherapy :
- Concurrent radiotherapy involving target lesions used for this study.
- Concurrent palliative radiation (but radiation for non-target lesions is allowed if other target lesions are available outside the involved field)
- previous pre-operative or post-operative radiotherapy within 3 months before study treatment
- History of other malignant tumors within the last 5 years, except basal cell carcinoma or curatively excised cervical carcinoma in situ
- Known brain metastases unless adequately treated (surgery or radiotherapy) with no evidence of progression and neurologically stable off anticonvulsants and steroids
- Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) ≤ 1 year before enrolment
- Inadequate pulmonary function according to the Investigator's judgment, history of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or evidence of interstitial lung disease on baseline chest CT scan
- Known active Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or HIV infection
- Serious concomitant disease or medical condition that in the judgment of the investigator renders the patient at high risk from treatment complication
- Any systemic disease requiring oral intake of corticosteroids (except for replacement therapy of corticosteroids - hydrocortisone in case of adrenal or pituitary insufficiency)
- Hearing loss ≥ Grade 3 (CTCAE v4.03)
- Patient pregnant or breast feeding, or planning to become pregnant within 8 weeks after the end of treatment
- Patient (male or female) is not willing to use highly effective methods of contraception (per institutional standard) during treatment and for 8 weeks (male or female) after the end of treatment.
- Concurrent treatment with other experimental drugs or participation in another clinical trial with any investigational drug within 28 days prior to treatment start
- Concurrent treatment with inhibitors (e.g. itraconazole, ketoconazole) and inducers (e.g. phenytoin, rifampicin) of Cytochrome P450 3A4 (CYP3A4) and / or the multidrug efflux pump P-glycoprotein (PgP).
- Known drug abuse/alcohol abuse
- Peripheral polyneuropathy ≥ Grade 2 (CTCAE v4.03)
- Active chronic inflammatory bowel disease
- Any condition which might interfere with study objectives (e.g. infections) or would limit the patient's ability to complete the study in the opinion of the investigator
- Patient who has been incarcerated or involuntarily institutionalized by court order or by the authorities. (AMG §40, Abs. 1 No. 4)
- Affected persons who might be dependent on the sponsor or the investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
Patients receive Everolimus orally, 10 mg/day. The end of study will be performed when tumor progression has been observed for 28 patients. Patients who are still under treatment at that time may continue with chemotherapy at the discretion of the investigator, but will be excluded from the study. |
Formulation: 10 mg/day Route: oral (tablet)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events (AEs)
Time Frame: approx. 18 month
|
Incidence of adverse events (AEs) overall and by severity, and serious adverse events (SAEs). Severity will be assessed using the National Cancer Institute-Common Toxicity Criteria (NCI-CTC) for Adverse Events, version 4.03 (CTCAEv4.03). To evaluate tolerability and safety of everolimus in second-line treatment of poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumors G3. |
approx. 18 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression free survival (PFS)
Time Frame: approx. 18 month
|
Progression free survival (PFS) as the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease but it does not get worse as per local radiology assessment using Response Evaluation Criteria in Solid Tumors (RECIST 1.1.)
|
approx. 18 month
|
Objective response rate (ORR)
Time Frame: approx. 18 month
|
Objective response rate defined as the rate of best overall response (CR+PR), determined by RECIST V 1.1.
|
approx. 18 month
|
Disease control rate (DCR)
Time Frame: approx. 18 month
|
Disease control rate defined as the rate of best overall response and stable disease (CR+PR+SD), determined by RECIST V 1.1.
|
approx. 18 month
|
Duration of response (DR)
Time Frame: approx. 18 month
|
Duration of response is defined as the time from onset of the first objective tumor response (CR/PR) to objective tumor progression or death from any cause.
|
approx. 18 month
|
Overall Survival (OS)
Time Frame: approx. 18 month
|
OS is defined as the time from date of randomization to the date of death from any cause.
If a patient is not known to have died at the date of analysis cut-off, the OS will be censored at the last date of contact.
|
approx. 18 month
|
Quality of life
Time Frame: approx. 18 month
|
Quality of life (HRQoL) will be evaluated using the European Organisation for Research and Treatment of Cancer (EORTC), to assess the quality of life of cancer patients questionnaire (QLQ-C30)
|
approx. 18 month
|
chromogranin A & B
Time Frame: approx. 12 month
|
Percentage of patients showing normalization or a decrease of chromogranin A & B
|
approx. 12 month
|
Time to Progression (TTP)
Time Frame: approx. 18 month
|
Time to progression (TTP) is the time from date of start of treatment to the date of event defined as the first documented progression due to underlying cancer.
|
approx. 18 month
|
neuron-specific enolase
Time Frame: approx. 12 month
|
Percentage of patients showing normalization or a decrease of neuron-specific enolase
|
approx. 12 month
|
progastrin releasing peptide
Time Frame: approx. 12 month
|
Percentage of patients showing normalization or a decrease of progastrin releasing peptide.
|
approx. 12 month
|
Correlation mTOR pathway components in tumor tissue to tumor response
Time Frame: approx. 18 month
|
To explore expression of mTOR pathway components in tumor tissue (archive) in correlation to tumor response
|
approx. 18 month
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Marianne Pavel, Prof. Dr., Charité-Universitätsmedizin
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Adenocarcinoma
- Neoplasms, Glandular and Epithelial
- Disease Attributes
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Disease Progression
- Carcinoma
- Carcinoma, Neuroendocrine
- Neuroendocrine Tumors
- Physiological Effects of Drugs
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Everolimus
Other Study ID Numbers
- AIO-NET-0112
- CRAD001KDE55T (Other Grant/Funding Number: Novartis)
- 2012-004550-28 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuroendocrine Carcinoma, Grade 3
-
Samsung Medical CenterMerck KGaA, Darmstadt, GermanyCompletedNeuroendocrine Carcinoma, Grade 3Korea, Republic of
-
Peking Union Medical College HospitalHarbin Medical University; The First Affiliated Hospital of Xiamen UniversityRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3China
-
Qilu Hospital of Shandong UniversityThe Affiliated Hospital of Qingdao University; Shandong Provincial Hospital... and other collaboratorsNot yet recruitingNeuroendocrine Tumor Grade 3
-
University of Roma La SapienzaRecruitingNeuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1Italy
-
Tianjin Medical University Cancer Institute and...RecruitingPancreatic Carcinoma | Neuroendocrine Carcinoma | Neuroendocrine Tumor Grade 3China
-
ViMREX GmbHFrankfurter Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus...Active, not recruitingVulvar Intraepithelial Neoplasia Grade 2 | Vulvar Intraepithelial Neoplasia Grade 3Germany
-
University of California, San FranciscoMerck Sharp & Dohme LLCRecruitingNeuroendocrine Tumors | High Grade Neuroendocrine Carcinoma, Any Site | Well-Differentiated Neuroendocrine CarcinomaUnited States
-
University of California, San FranciscoMerck Sharp & Dohme LLCCompletedHigh Grade Malignant Neuroendocrine Carcinoma (Diagnosis)United States
-
Dwight OwenBristol-Myers SquibbActive, not recruitingNeuroendocrine Tumors | Small-cell Lung Cancer | Neuroendocrine Carcinoma | Large Cell Neuroendocrine Carcinoma | Lung Cancer Stage IV | Recurrent Small Cell Lung Carcinoma | Refractory Small Cell Lung Carcinoma | Metastatic Neuroendocrine Carcinoma | Grade I Neuroendocrine Carcinoma | Grade II Neuroendocrine... and other conditionsUnited States
-
Baylor Research InstituteTaiho Oncology, Inc.RecruitingHigh-grade Extra Pulmonary Neuroendocrine CancerUnited States
Clinical Trials on Everolimus (Afinitor®)
-
Guangdong Provincial People's HospitalNovartisUnknownNeuroendocrine Tumors | Carcinoid TumorChina
-
NYU Langone HealthNovartis Pharmaceuticals; The Children's Tumor FoundationCompletedNeurofibromatosis Type IIUnited States
-
Dana-Farber Cancer InstituteNovartis PharmaceuticalsCompletedTuberous Sclerosis Complex | TSC1 | TSC2 | MTORUnited States
-
Swiss Group for Clinical Cancer ResearchCompletedProstate CancerSwitzerland
-
Novartis PharmaceuticalsTerminatedHepatocellular CarcinomaHong Kong, Taiwan, Thailand
-
Hopital FochCompleted
-
Washington University School of MedicineTyrogenexTerminatedAdenocarcinoma | Pancreatic NeoplasmsUnited States
-
Queen Mary University of LondonAstraZeneca; Cancer Research UKTerminatedMetastatic Clear Cell Renal CarcinomaUnited Kingdom
-
Novartis PharmaceuticalsCompleted
-
NYU Langone HealthCompletedEpilepsy | Tuberous Sclerosis Complex | Focal Cortical DysplasiaUnited States